The most common adverse events associated with<unk>  (all doses of<unk>  cumulatively greater than or equal to 5% vs. placebo) were upper respiratory tract infection (6.9% vs. 4.8%), akathisia (6.6% vs. 3.2%), weight gain (6.3% vs. 0.8%), and nasopharyngitis (5.0% vs. 1.6%).
Brexpiprazole
Lorpiprazole
Mepiprazole
Aripiprazole
Pirlindole
Risperidone
Electroconvulsive therapy
Edivoxetine